Zheng Huo-Liang, Yang Run-Ze, Xu Wen-Ning, Liu Tao, Chen Peng-Bo, Zheng Xin-Feng, Li Bo, Jiang Lei-Sheng, Jiang Sheng-Dan
Department of Clinic of Spine Center, Xinhua Hospital, Shanghai Jiaotong, University School of Medicine, Shanghai 200082, China.
Aging (Albany NY). 2020 Sep 20;12(18):18571-18587. doi: 10.18632/aging.103849.
Many studies have revealed the function of long noncoding RNA (LncRNA) in regulating tumorigenesis of osteosarcoma (OS). As a subgroup of LncRNA, small nucleolar RNA host genes (SNHGs) have emerged as potentially important in OS. According to our recent findings, small nucleolar RNA host gene 22 (SNHG22) plays an important role in inhibiting the growth and metastasis of OS. However, the underlying mechanism of SNHG22 in regulating OS progression remains unknown. In this study, we confirmed that SNHG22 was downregulated in OS, and the overexpression of SNHG22 significantly inhibited OS progression and . Meanwhile, overexpression of SNHG22 also inhibited the migration and proliferation of human umbilical vein endothelial cells (HUVECs) and prevented the epithelial-to-mesenchymal transition (EMT) in OS. Furthermore, the interaction between miR-4492 and SNHG22 we previously predicted was validated by RNA pull-down assays and RNA immunoprecipitation assays. Dual-luciferase reporter assays showed that SNHG22 could directly interact with miR-4492 and upregulate the expression of NK-κB inhibitor-interacting Ras-like 2 (NKIRAS2) by its competing endogenous RNA (ceRNA) activity on miR-4492. In conclusion, our study has clarified the function of SNHG22 in OS progression and suggests a novel therapeutic target for OS.
许多研究已经揭示了长链非编码RNA(LncRNA)在调节骨肉瘤(OS)肿瘤发生中的作用。作为LncRNA的一个亚组,小核仁RNA宿主基因(SNHGs)在OS中已显示出潜在的重要性。根据我们最近的发现,小核仁RNA宿主基因22(SNHG22)在抑制OS的生长和转移中起重要作用。然而,SNHG22调节OS进展的潜在机制仍然未知。在本研究中,我们证实SNHG22在OS中表达下调,SNHG22的过表达显著抑制OS进展。同时,SNHG22的过表达还抑制了人脐静脉内皮细胞(HUVECs)的迁移和增殖,并阻止了OS中的上皮-间质转化(EMT)。此外,我们之前预测的miR-4492与SNHG22之间的相互作用通过RNA下拉试验和RNA免疫沉淀试验得到验证。双荧光素酶报告试验表明,SNHG22可以直接与miR-4492相互作用,并通过其对miR-4492的竞争性内源RNA(ceRNA)活性上调NK-κB抑制剂相互作用Ras样蛋白2(NKIRAS2)的表达。总之,我们的研究阐明了SNHG22在OS进展中的作用,并为OS提出了一个新的治疗靶点。